Zoetis has announced that Apoquel (oclacitinib), its treatment for atopic dermatitis and associated pruritis, will be available in palatable chew form in the UK next year, following the grant of a marketing authorisation.

Developed by Zoetis, Apoquel is a prescription-only Janus kinase (JAK) inhibitor approved for veterinary use that targets the itch and inflammation pathway.

Ben Hurst, Product Manager, Zoetis UK said: "Atopic dermatitis is one of the most common allergies in dogs, affecting approximately 10% of the dog population1.

"Itching caused by an allergic skin disease can impact the quality of life for both the dog and its owner unless they are controlled with effective management.

"Apoquel chewable tablets now offer a new, convenient and palatable solution for dog owners."

Apoquel chewable tablets are administered twice daily for up to 14 days (at 0.4 to 0.6 mg/kg), then once daily for maintenance therapy. 

Zoetis says marketing authorisation for the EU market is expected later this year following the Committee for Medicinal Products for Veterinary Use (CVMP) positive opinion received on 7th October 2021. 


  1. Zoetis Market Research: Apoquel Cytopoint Vet Tracker - Veterinarians Wave 2 July 2020

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.